What the FDA labels say about taking them together

Atazanavir and cabozantinib

Cabozantinib's FDA label (Cometriq) of October 18, 2025 names atazanavir in its drug interactions section; the atazanavir labels PlainMeds reads (2) do not name cabozantinib. The cabozantinib label: “Avoid taking a strong CYP3A4 inhibitor while taking COMETRIQ or reduce the dosage of COMETRIQ if concomitant use with strong CYP3A4 inhibitors cannot be avoided.”

Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the cabozantinib FDA label on DailyMed (effective October 19, 2025, Exelixis, Inc.).

What does the atazanavir label say about cabozantinib?

Atazanavir's label (effective August 6, 2025) and its 1 other brand-application label do not name cabozantinib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed

What does the cabozantinib label say about atazanavir?

Cometriq label (Exelixis, Inc., October 18, 2025), drug interactions
Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) while taking COMETRIQ or reduce the dosage of COMETRIQ if concomitant use with strong CYP3A4 inhibitors cannot be avoided [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )].

Source: FDA drug label (Cometriq, NDA203756), Exelixis, Inc., effective October 18, 2025 (SPL set 1a0c3bea-c87b-4d25-bb44-5f0174da6b34), via openFDA

Source: FDA drug label (CABOMETYX), Exelixis, Inc., effective October 19, 2025 (SPL set 3850cce2-6137-42e5-a792-d318c4a4b3b5), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

4Atazanavir generic labelers

0Cabozantinib generic labelers

	Atazanavir	Cabozantinib
Labeled for	HIV	n/a
Boxed warning	No	No
Pharmacy cost (NADAC)	$2.23 per capsule 300 mg capsule	n/a
Shortage now	No current entry	No current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?

Atazanavir: the full record
Cabozantinib: the full record
Check more medicines together: up to five at once